Join
Live feed
·
PRReleasevia Quantisnow
Prevail Therapeutics Inc. logo

Prevail Therapeutics Announces First Patient Dosed in Phase 1/2 PROCLAIM Clinical Trial Evaluating PR006 for the Treatment of Frontotemporal Dementia Patients with GRN Mutations

ByQuantisnow·Wall Street's wire, on your screen.
PRVL· Prevail Therapeutics Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track PRVL (Prevail Therapeutics Inc.) and more on Quantisnow.